

Merus Labs International Inc.  
Form 6-K  
July 05, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **July 2016**

Commission File No. **000-30082**

**MERUS LABS INTERNATIONAL INC.**

(Translation of registrant's name into English)

**100 Wellington St. West, Suite 2110 P.O. Box 151**

**Toronto, ON M5K 1H1**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F  
Form 20-F [  ]      **Form 40-F [X]**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(1) [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule  
101(b)(7) [  ]

**SUBMITTED HEREWITH**

**Exhibits**

99.1 Press Release dated July 4th, 2016 - Merus Announces Reduced Leverage and Provides Business Update

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 4, 2016

**MERUS LABS INTERNATIONAL INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer

= "margin-top:12px;margin-bottom:0px" ALIGN="center">N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

Mark Newman, Senior Vice President and Chief Financial Officer of SunCoke Energy, Inc. (the Company), will participate in the Oppenheimer 2nd Annual 1-on-1 Investor Conference on February 7, 2012 in London, England.

The slides that Mr. Newman will use at the conference are attached hereto as Exhibit 99.1 and incorporated herein by reference.

In addition, on February 6, 2012, the Company provided supplemental financial information about segment revenues. Such information is attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in this Current Report on Form 8-K being furnished pursuant to Items 7.01 and 9.01 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit No.	Exhibit
99.1	February 2012 Conference Slides.
99.2	Supplemental Financial Information Segment Revenues

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**SUNCOKE ENERGY, INC.**

By: /s/ Fay West  
Fay West  
Vice President and Controller

Date: February 6, 2012

**EXHIBIT INDEX**

Exhibit No.	Exhibit
99.1	February 2012 Conference Slides.
99.2	Supplemental Financial Information Segment Revenues